|
|
Blood, 15 November 2006, Vol. 108, No. 10, pp. 3560-3563.
Prepublished online as a Blood First Edition Paper on July 27, 2006; DOI 10.1182/blood-2006-03-010835.
Previous Article | Table of Contents | Next Article 
NEOPLASIA Brief report
Overexpression of CEBPA resulting from the translocation t(14;19)(q32;q13) of human precursor B acute lymphoblastic leukemia
Elise Chapiro,
Lisa Russell,
Isabelle Radford-Weiss,
Christian Bastard,
Michel Lessard,
Stephanie Struski,
Helene Cave,
Sandra Fert-Ferrer,
Carole Barin,
Odile Maarek,
Veronique Della-Valle,
Jonathan C. Strefford,
Roland Berger,
Christine J. Harrison,
Olivier A. Bernard,
Florence Nguyen-Khac, the Groupe Francophone de Cytogénétique Hématologique
From the Assistance Publique-Hôpitaux de Paris (AP-HP) Service d'Hématologie Biologique, Hôpital Pitié-Salpêtrière, Paris, France; Institut National de la Santé etde la Recherche Médicale (INSERM), E0210, Paris, France; University Paris VI, Paris, France; Leukaemia Research Cytogenetics Group, Cancer Sciences Division, University of Southampton, United Kingdom; University René Descartes, Paris, France; AP-HP, Laboratoire de Cytogénétique, Hôpital Necker-Enfants Malades, Paris, France; Laboratoire de Génétique oncologique, Rouen, France; Laboratoire d'Hématologie, Hôpital Hautepierre, Strasbourg, France; AP-HP, Laboratoire de Biochimie Génétique, Hôpital Robert Debré, Paris, France; Laboratoire de Génétique, Chambéry, France; Laboratoire de Génétique, Tours, France; and AP-HP, Laboratoire d'Hématologie, Hôpital Saint-Louis, Paris, France.
Subtle variation in the expression or function of a small group of transcription factors can drive leukemogenesis. The CEBPA protein is known to regulate the balance between cell proliferation and differentiation during early hematopoietic development and myeloid differentiation. In human myeloid leukemia, CEBPA is frequently inactivated by mutation and indirect and posttranslational mechanisms, in keeping with tumor suppressor properties. We report that CEBPA is activated by juxtaposition to the immunoglobulin gene enhancer upon its rearrangement with the immunoglobulin heavy-chain locus in precursor B-cell acute lymphoblastic leukemia harboring t(14;19)(q32;q13). Overexpression of apparently normal CEBPA RNA or protein was observed in 6 patients. These data indicate that CEBPA may exhibit oncogenic as well as tumor suppressor properties in human leukemogenesis.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Article in Blood Online:
-
CEBPA dosage in leukemogenesis
- Thomas Mercher and D. Gary Gilliland
Blood 2006 108: 3234.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
L. J. Russell, M. Capasso, I. Vater, T. Akasaka, O. A. Bernard, M. J. Calasanz, T. Chandrasekaran, E. Chapiro, S. Gesk, M. Griffiths, et al.
Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia
Blood,
September 24, 2009;
114(13):
2688 - 2698.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Pabst and B. U. Mueller
Complexity of CEBPA Dysregulation in Human Acute Myeloid Leukemia
Clin. Cancer Res.,
September 1, 2009;
15(17):
5303 - 5307.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. H. I. M. Hollink, M. M. van den Heuvel-Eibrink, and C. M. Zwaan
CEBPA resembles Roman god Janus
Blood,
June 25, 2009;
113(26):
6501 - 6502.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Koschmieder, B. Halmos, E. Levantini, and D. G. Tenen
Dysregulation of the C/EBP{alpha} Differentiation Pathway in Human Cancer
J. Clin. Oncol.,
February 1, 2009;
27(4):
619 - 628.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. T. J. Wierenga, E. Vellenga, and J. J. Schuringa
Maximal STAT5-Induced Proliferation and Self-Renewal at Intermediate STAT5 Activity Levels
Mol. Cell. Biol.,
November 1, 2008;
28(21):
6668 - 6680.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. J. Russell, T. Akasaka, A. Majid, K.-j. Sugimoto, E. Loraine Karran, I. Nagel, L. Harder, A. Claviez, S. Gesk, A. V. Moorman, et al.
t(6;14)(p22;q32): a new recurrent IGH@ translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL)
Blood,
January 1, 2008;
111(1):
387 - 391.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. J. Wouters, M. A. Jorda, K. Keeshan, I. Louwers, C. A. J. Erpelinck-Verschueren, D. Tielemans, A. W. Langerak, Y. He, Y. Yashiro-Ohtani, P. Zhang, et al.
Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1
Blood,
November 15, 2007;
110(10):
3706 - 3714.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Akasaka, T. Balasas, L. J. Russell, K.-j. Sugimoto, A. Majid, R. Walewska, E. L. Karran, D. G. Brown, K. Cain, L. Harder, et al.
Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL)
Blood,
April 15, 2007;
109(8):
3451 - 3461.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|